ZN-d5
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis
Conditions
Amyloidosis, AL Amyloidosis
Trial Timeline
Nov 30, 2021 → Feb 14, 2024
NCT ID
NCT05199337About ZN-d5
ZN-d5 is a phase 1/2 stage product being developed by Zentalis Pharmaceuticals for Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05199337. Target conditions include Amyloidosis, AL Amyloidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05199337 | Phase 1/2 | Completed |
| NCT04854174 | Phase 1 | Completed |
| NCT04500587 | Phase 1 | Completed |
Competing Products
20 competing products in Amyloidosis